Evaluation of hyperthermic intrathoracic chemotherapy (HITHOC)

Not yet recruiting

• Conditions: C45.0; C38.4; Mesothelioma of pleura; Pleura

• Registration Number: DRKS00015012
• Lead Sponsor: Abteilung für Thoraxchirurgie, Universitätsklinikum Regensburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

HITHOC after surgical cytoreduction
- malignant pleural tumor

Exclusion Criteria

- therapy without HITHOC
- HITHOC without surgical cytoreduction

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality assurance and implementation of intraoperative HITOC after surgical cytoreduction

Secondary Outcome Measures

Name	Time	Method
- Dosing of intrathoracic chemotherapy (cisplatin) during HITOC<br>- Postoperative renal insufficiency including conservative therapy and dialysis after HITOC, also depending to the dosage of cisplatin<br>- In-hospital mortality after HITOC and surgical cytoreduction<br>- Postoperative complications and morbidity (e.g. surgical revision)<br>- Technical development of HITOC, changes in perioperative management and extend of complications within the last years